Perrigo Co.’s agreement with auditor Ernst & Young over an accounting issue, announced late Tuesday, paves the way for the drugmaker to file its delayed 10K annual report and removes one problem from CEO John Hendrickson’s overfull plate. The Dublin drugmaker reiterated sales guidance for 2017 and said it would pay down debt to protect its...

Source: Wall Street Journal April 26, 2017 00:45 UTC